AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ is starting to see the benefits of the divestment strategy adopted by chief executive Pascal Soriot after fending off a takeover attempt by Pfizer four years ago, which has seen

The handover: Pfizer reshapes itself for a new era

So what are Bourla’s plans to keep Pfizer performing for shareholders and patients? ... We need to make sure that we segregate it from Pfizer by providing them substantial autonomy, ”said Albert Bourla.

AZ says target of $45bn sales by 2023 still achievable

The plan, first announced when AZ was fending off an unwanted takeover bid by Pfizer, has often looked overly ambitious in the intervening years as it suffered patent losses on

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)